George Ross - Acura Pharmaceuticals Independent Director
| ACURDelisted Stock | USD 0.05 0.00 0.00% |
Director
Mr. George K. Ross serves as an Independent Director of Acura Pharmaceutical Technologies, Inc. Since January, 2008. Since April 2002, Mr. Ross was a consultant to early stage businesses and a financial investor. From April 1, 2015 until its sale in March 2017, Mr. Ross was an advisor to GP Shopper LLC, a provider of mobile solutions for retail and brands. From July 2005 through December 2010 he served as Executive Director, Foundations and Partnerships for World Vision U.S. in New York City. His business career has included senior financial officer and board member positions with both public and private companies in diverse industries. Mr. Ross was Executive Vice President and Chief Financial Officer and a board member of Tier Technologies Inc. from February 1997 to January 2000, which became a public company during this period since 2008.
| Age | 75 |
| Tenure | 16 years |
| Phone | 847 705 7709 |
| Web | https://www.acurapharm.com |
Acura Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3842) % which means that it has lost $0.3842 on every $100 spent on assets. This is way below average. Acura Pharmaceuticals' management efficiency ratios could be used to measure how well Acura Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 105 K in liabilities with Debt to Equity (D/E) ratio of 2.4, implying the company greatly relies on financing operations through barrowing. Acura Pharmaceuticals has a current ratio of 0.84, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Acura Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Acura Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Acura Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Acura to invest in growth at high rates of return. When we think about Acura Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 12 records | DIRECTOR Age | ||
| Calvin Roberts | Alimera Sciences | 64 | |
| Mark Brooks | Alimera Sciences | 50 | |
| Daniel Mitchell | ARCA Biopharma | 57 | |
| Anders Hove | ARCA Biopharma | 49 | |
| Mary Szela | Alimera Sciences | 55 | |
| John Snisarenko | Alimera Sciences | N/A | |
| Peter Pizzo | Alimera Sciences | 50 | |
| Garheng Kong | Alimera Sciences | 42 | |
| Brian Halak | Alimera Sciences | 45 | |
| Raymond Woosley | ARCA Biopharma | 71 | |
| Linda Grais | ARCA Biopharma | 61 | |
| James Largent | Alimera Sciences | 67 | |
Management Performance
| Return On Asset | -0.38 |
Acura Pharmaceuticals Leadership Team
Elected by the shareholders, the Acura Pharmaceuticals' board of directors comprises two types of representatives: Acura Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Acura. The board's role is to monitor Acura Pharmaceuticals' management team and ensure that shareholders' interests are well served. Acura Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Acura Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| George Ross, Independent Director | ||
| Robert Jones, CEO and President and Director | ||
| Bruce Wesson, Independent Director | ||
| Mr CPA, Treasurer VP | ||
| Peter Clemens, CFO, Principal Accounting Officer, Sr. VP and Secretary | ||
| Albert Brzeczko, VP of Technical Affairs | ||
| Immanuel Thangaraj, Independent Director | ||
| James Emigh, Vice President - Corporate Development | ||
| Robert Seiser, VP, Treasurer and Corporate Controller | ||
| Bradley Rivet, VP of Marketing | ||
| William Skelly, Independent Director |
Acura Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Acura Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.38 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.49) % | ||||
| Current Valuation | 3.49 M | ||||
| Shares Outstanding | 65.09 M | ||||
| Shares Owned By Insiders | 19.27 % | ||||
| Shares Owned By Institutions | 3.00 % | ||||
| Number Of Shares Shorted | 89.85 K | ||||
| Price To Earning | 125.00 X | ||||
| Price To Book | 24.11 X |
Pair Trading with Acura Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acura Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acura Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Acura Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acura Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acura Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acura Pharmaceuticals to buy it.
The correlation of Acura Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acura Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acura Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acura Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in Acura OTC Stock
If you are still planning to invest in Acura Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acura Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |